NCT01535989View on ClinicalTrials.gov

Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphoma

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

December 31, 2011

Primary Completion Date

June 30, 2016

Study Completion Date

June 30, 2016

Conditions
B-cell Lymphoma Refractory
Interventions
DRUG

Inotuzumab Ozogamicin

starting dose 0.8 mg/m2, d1 administration, q4wks

DRUG

Temsirolimus

starting dose of 15mg, weekly administration, q4ws

Trial Locations (3)

3010

InselSpital, Universitätsspital Bern, Bern

6500

Oncology Institute of Southern Switzerland, Bellinzona

9007

Kantonsspital St.Gallen, San Gallen

All Listed Sponsors
lead

Cristiana Sessa

OTHER

NCT01535989 - Study of Inotuzumab Ozogamicin + Temsirolimus in Patients With Relapsed or Refractory CD22+ B-cell NHLymphoma | Biotech Hunter | Biotech Hunter